British Biotech in collaboration
Selected Abstract
British Biotech in collaboration with ImmunoGen to develop and commercialize huN901-DM1 for the treatment of small cell lung cancer.
Business & Health Editors OXFORD, EnglandBUSINESS WIREMay 5, 2000 British Biotech and ImmunoGen Inc. ( ImmunoGen ), a NASDAQ listed biopharmaceutical company, have today announced that they have entered into a collaborative agreement to develop and commercialize ImmunoGen's huN901-DM1, targeted ... May 5, 2000; Business Wire
Read the full article with a free-trial membership at HighBeam Research
Related Articles 1.
British Biotech in collaboration with ImmunoGen to develop and commercialize huN901-DM1 for the treatment of small cell lung cancer.
2.
BRITISH BIOTECH'S SIX-MONTH LOSS DECREASED TO US$12.2M.(Statistical Data Included)
3.
British Biotech Interim Results for the Six Months Ended October 31, 2002.
4.
British Biotech plc -- ``British Biotech'' -- Interim Results for the Six Months Ended October 31, 2001.
|
